Vectura Group plc
http://www.vectura.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vectura Group plc
Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar
Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.
AbbVie Cranks Up Temperature In IBD Market With Celsius Buyout
The drug maker is spending $250m to acquire privately held Celsius and its lead candidate, a monoclonal antibody targeting TREM1 in inflammatory bowel disease.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
BIO: Upbeat Zevra Advances Promising Rare Disease Portfolio
With the urea cycle disorder treatment Olpruva launched and the NPC therapy arimoclomol closing in on US approval, Zevra is one to watch in the rare disease space.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Services
- Contract Manufacturing Organization
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Other Names / Subsidiaries
-
- Activaero GmbH
- Innovata plc
- Philip Morris International Inc.
- Quadrant Healthcare
- SkyePharma PLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice